GlassScriptPhysician profile
Celeste H Stone
NPI 1750407870
$3,690.75
in general payments reported to CMS, 2019-2025
47 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $790 · 2022: $1,372 · 2023: $1,284 · 2024: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,430 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,429.50 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $482.81 | 2021-2023 | Tagrisso, Enhertu |
| Novartis Pharmaceuticals Corporation | $270.78 | 2021-2023 | Kisqali |
| Bayer Healthcare Pharmaceuticals INC. | $203.60 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $186.75 | 2021-2023 | Keytruda, Lynparza |
| Amgen INC. | $184.28 | 2021-2023 | Kyprolis, Xgeva, Vectibix |
| Lilly USA, LLC | $178.21 | 2021-2024 | Retevmo, Jaypirca, Verzenio |
| E.R. Squibb & Sons, L.L.C. | $163.05 | 2022-2023 | Opdivo, Pomalyst, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $155.46 | 2021-2023 | Alunbrig, Iclusig |
| Daiichi Sankyo INC. | $144.47 | 2021-2023 | Enhertu, Injectafer |
| Genzyme Corporation | $112.83 | 2022-2023 | |
| Janssen Biotech, INC. | $111.67 | 2021-2023 | Darzalex, Imbruvica |
| Eisai INC. | $106.28 | 2022-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $93.52 | 2021-2023 | Imbruvica |
| Rigel Pharmaceuticals, INC. | $87.54 | 2022-2023 | Rezlidhia, Tavalisse |
| Paratek Pharmaceuticals, INC. | $83.29 | 2023-2024 | Nuzyra |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $79.70 | 2022-2023 | Zoladex |
| Celgene Corporation | $77.30 | 2022-2023 | Pomalyst |
| Aveo Pharmaceuticals, INC. | $71.03 | 2021-2022 | |
| Mirati Therapeutics, INC. | $64.51 | 2023 | Krazati |
| Urgo Medical North America, LLC | $63.75 | 2023-2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Urgok2 |
| Abbvie INC. | $60.27 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $57.83 | 2022-2023 | Libtayo |
| Pfizer INC. | $56.21 | 2021-2022 | |
| Molnlycke Health Care US, LLC | $49.19 | 2024 | Mepilex Border Ag, Mepitel Ag, Mepilex Ag |
| Glaxosmithkline, LLC. | $44.98 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $36.83 | 2021-2022 | |
| Incyte Corporation | $35.30 | 2022-2023 | Jakafi |
| Array Biopharma INC | $34.55 | 2022-2023 | Braftovi, Lorbrena, Xalkori |
| Jazz Pharmaceuticals INC. | $32.76 | 2021-2022 | |
| Organogenesis INC. | $31.64 | 2024 | |
| Solventum Corporation | $29.95 | 2024 | Activ.A.C., V.A.C. Dermatac |
| Taiho Oncology, INC. | $27.20 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.09 | 2021 | |
| Sobi, INC | $24.06 | 2022 | |
| Pharmaessentia USA Corporation | $21.39 | 2023 | Besremi |
| Karyopharm Therapeutics INC. | $19.87 | 2023 | Xpovio |
| Deciphera Pharmaceuticals INC. | $19.59 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $19.41 | 2021 | |
| Acceleron Pharma, INC. | $18.32 | 2021 | |
| Blue Earth Diagnostics | $17.05 | 2021 | |
| Adaptive Biotechnologies Corporation | $17.01 | 2023 | Clonoseq |
| Kyowa Kirin, INC. | $16.91 | 2021 | |
| Seagen INC. | $16.64 | 2021 | |
| Coherus Oncology, INC. | $15.56 | 2021 | |
| Gilead Sciences, INC. | $14.99 | 2022 | |
| Mylan Institutional INC. | $14.00 | 2023 | Fulphila |
| Smith+Nephew, INC. | $13.32 | 2024 | Renasys Go V2 Home, Pico |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celeste Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.